Terms: = Chronic Myelogenous Leukemia AND YWHAE, P62258, 7531, ENSG00000108953, 14-3-3 epsilon, FLJ45465, MDS, MDCR, KCIP-1, 14-3-3E
529 results:
1. Cytosine analogues as DNA methyltransferase substrates.
Wojciechowski M; Czapinska H; Krwawicz J; Rafalski D; Bochtler M
Nucleic Acids Res; 2024 Aug; 52(15):9267-9281. PubMed ID: 38966999
[TBL] [Abstract] [Full Text] [Related]
2. miR-15a targets the HSP90 co-chaperone Morgana in chronic myeloid leukemia.
Poggio P; Rocca S; Fusella F; Ferretti R; Ala U; D'Anna F; Giugliano E; Panuzzo C; Fontana D; Palumbo V; Carrà G; Taverna D; Gambacorti-Passerini C; Saglio G; Fava C; Piazza R; Morotti A; Orso F; Brancaccio M
Sci Rep; 2024 Jul; 14(1):15089. PubMed ID: 38956394
[TBL] [Abstract] [Full Text] [Related]
3. Analysis of CSF3R mutations in atypical chronic myeloid leukemia and other myeloid malignancies.
Kim SY; Song IC; Kim J; Kwon GC
Ann Diagn Pathol; 2024 Aug; 71():152317. PubMed ID: 38642470
[TBL] [Abstract] [Full Text] [Related]
4. Role of reactive oxygen species in myelodysplastic syndromes.
Jing Q; Zhou C; Zhang J; Zhang P; Wu Y; Zhou J; Tong X; Li Y; Du J; Wang Y
Cell Mol Biol Lett; 2024 Apr; 29(1):53. PubMed ID: 38616283
[TBL] [Abstract] [Full Text] [Related]
5. Molecular relapse monitoring reveals the domination of impaired NK cell education over impaired inhibition in missing KIR-ligand recognition in patients after unrelated hematopoietic stem cell transplantation for malignant diseases.
Nowak J; Witkowska A; Rogatko-Koroś M; Malinowska A; Graczyk-Pol E; Nestorowicz-Kałużna K; Flaga A; Szlendak U; Wnorowska A; Gawron A
HLA; 2024 Feb; 103(2):e15364. PubMed ID: 38312022
[TBL] [Abstract] [Full Text] [Related]
6. [Biological and clinical significance of TP53 mutations in myelodysplastic syndrome and acute myeloid leukemia].
Kojima K
Rinsho Ketsueki; 2023; 64(9):955-961. PubMed ID: 37793871
[TBL] [Abstract] [Full Text] [Related]
7. Clinical Features of Clonal Cytogenetic Abnormalities in Philadelphia-negative Cells Developed During Tyrosine Kinase Inhibitor Treatment.
Oiwa K; Lee S; Fujita K; Ueda T; Yamauchi T
Intern Med; 2024 Mar; 63(5):729-732. PubMed ID: 37468240
[TBL] [Abstract] [Full Text] [Related]
8. De nove Philadelphia chromosome-positive myelodysplastic syndromes with complex karyotype and p230
Ma J; Guan J; Chen B
Hematology; 2023 Dec; 28(1):2220220. PubMed ID: 37288817
[TBL] [Abstract] [Full Text] [Related]
9. Philadelphia chromosome- positive myelodysplastic syndrome with single lineage dysplasia.
Kumar A; Tilak V; Arora D; Marisha ; Rahul ; Gautam D; Ali A
Cancer Genet; 2023 Aug; 276-277():12-16. PubMed ID: 37267684
[TBL] [Abstract] [Full Text] [Related]
10. The prognostic and therapeutic potential of HO-1 in leukemia and mds.
Sadeghi M; Fathi M; Gholizadeh Navashenaq J; Mohammadi H; Yousefi M; Hojjat-Farsangi M; Namdar A; Movasaghpour Akbari AA; Jadidi-Niaragh F
Cell Commun Signal; 2023 Mar; 21(1):57. PubMed ID: 36915102
[TBL] [Abstract] [Full Text] [Related]
11. Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies.
Connor MP; Loren AW; Hexner EO; Martin ME; Gill SI; Luger SM; Mangan JK; Perl AE; McCurdy SR; Pratz KW; Timlin C; Freyer CW; Carulli A; Catania C; Smith J; Hollander L; Zebrowski AM; Stadtmauer EA; Porter DL; Frey NV
Transplant Cell Ther; 2023 Feb; 29(2):113-118. PubMed ID: 36336258
[TBL] [Abstract] [Full Text] [Related]
12. Competitive evolved sub-clonal BCR::ABL1 and novel MSI2::PC fusion genes in myelodysplastic syndrome with isolated del(5q).
Zhang Y; Liu Y; Wang T; Wang H; Chen X; Cao P; Ma X; Liu M; Xu P; Bi H; Pan J; Jiang Y; Li X; Wang W; Liu H
Hematol Oncol; 2023 Feb; 41(1):178-181. PubMed ID: 36301018
[TBL] [Abstract] [Full Text] [Related]
13. Red Blood Cell Deformability and Distribution Width in Patients with Hematologic Neoplasms.
Lee JM; Suh JS; Kim YK
Clin Lab; 2022 Oct; 68(10):. PubMed ID: 36250843
[TBL] [Abstract] [Full Text] [Related]
14. [Radiation-induced hematopoietic disorders].
Ando K; Miyazaki Y
Rinsho Ketsueki; 2022; 63(9):981-990. PubMed ID: 36198562
[TBL] [Abstract] [Full Text] [Related]
15. Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute leukemia: Long-Term Study Outcomes.
Alatrash G; Saberian C; Bassett R; Thall PF; Ledesma C; Lu Y; Daher M; Valdez BC; Kawedia J; Popat U; Mehta R; Oran B; Nieto Y; Olson A; Anderlini P; Marin D; Hosing C; Alousi AM; Shpall EJ; Rondon G; Chen J; Qazilbash M; Champlin RE; Kebriaei P
Transplant Cell Ther; 2022 Aug; 28(8):501.e1-501.e7. PubMed ID: 35618218
[TBL] [Abstract] [Full Text] [Related]
16. Abnormal B-lymphoblasts in myelodysplastic syndromes and myeloproliferative neoplasms other than chronic myeloid leukemia.
Chan A; Kumar P; Gao Q; Baik J; Sigler A; Londono D; Liu Y; Arcila ME; Dogan A; Zhang Y; Roshal M; Xiao W
Cytometry B Clin Cytom; 2023 May; 104(3):243-252. PubMed ID: 34897961
[TBL] [Abstract] [Full Text] [Related]
17. ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine.
Rahmani NE; Ramachandra N; Sahu S; Gitego N; Lopez A; Pradhan K; Bhagat TD; Gordon-Mitchell S; Pena BR; Kazemi M; Rao K; Giricz O; Maqbool SB; Olea R; Zhao Y; Zhang J; Dolatshad H; Tittrea V; Tatwavedi D; Singh S; Lee J; Sun T; Steidl U; Shastri A; Inoue D; Abdel-Wahab O; Pellagatti A; Gavathiotis E; Boultwood J; Verma A
Blood Cancer J; 2021 Sep; 11(9):157. PubMed ID: 34548471
[TBL] [Abstract] [Full Text] [Related]
18. Blastic plasmacytoid dendritic-cell neoplasia: a challenging case report.
Koerber RM; Held SAE; Vonnahme M; Feldmann G; Wenzel J; Gütgemann I; Brossart P; Heine A
J Cancer Res Clin Oncol; 2022 Mar; 148(3):743-748. PubMed ID: 34529129
[TBL] [Abstract] [Full Text] [Related]
19. The cell body space occupied by the nucleus during the cell differentiation in human lymphocytic, granulocytic and erythroid cell lineages.
Smetana K; Klamová H; Mikulenková D; Čermák J; Otevřelová P; Karban J; Trněný M
Physiol Res; 2021 Nov; 70(5):701-707. PubMed ID: 34505521
[TBL] [Abstract] [Full Text] [Related]
20. Prophylactic or Preemptive Low-Dose Azacitidine and Donor Lymphocyte Infusion to Prevent Disease Relapse following Allogeneic Transplantation in Patients with High-Risk Acute myelogenous leukemia or Myelodysplastic Syndrome.
Guillaume T; Thépot S; Peterlin P; Ceballos P; Bourgeois AL; Garnier A; Orvain C; Giltat A; François S; Bris YL; Fronteau C; Planche L; Chevallier P
Transplant Cell Ther; 2021 Oct; 27(10):839.e1-839.e6. PubMed ID: 34224913
[TBL] [Abstract] [Full Text] [Related]
[Next]
